Profile data is unavailable for this security.
About the company
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH, is an Austria-based biopharmaceutical company. The Company operates in two segments such as Virology and Immunology. It develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose, platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients, this technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases.
- Revenue in EUR (TTM)9.46m
- Net income in EUR16.14m
- Incorporated2006
- Employees42.00
- LocationMarinomed Biotech AGHovengasse 25KORNEUBURG 2100AustriaAUT
- Phone+43 226290300
- Fax+43 226 290300500
- Websitehttps://www.marinomed.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marinomed Biotech AG | 9.46m | 16.14m | 32.75m | 42.00 | 1.77 | -- | 2.00 | 3.46 | 10.07 | 10.07 | 5.32 | -3.06 | 0.9978 | -- | 5.11 | 225,266.40 | 170.19 | -42.38 | -- | -63.46 | 65.35 | 11.22 | 170.57 | -90.11 | -- | 28.72 | 2.03 | -- | -48.31 | -5.03 | -126.89 | -- | -- | -- |
| Talphera Inc | 23.54k | -10.48m | 32.76m | 13.00 | -- | 1.99 | -- | 1,391.80 | -0.3808 | -0.378 | 0.0009 | 0.4207 | 0.0011 | -- | -- | 2,153.85 | -48.15 | -14.86 | -54.44 | -19.40 | -- | -- | -44,503.57 | -446.19 | -- | -- | 0.00 | -- | -100.00 | -- | -26.41 | -- | -- | -- |
| NicOx SA | 3.32m | -27.06m | 32.81m | 11.00 | -- | -- | -- | 9.90 | -0.3657 | -0.3657 | 0.045 | -0.0659 | 0.1034 | -- | 1.63 | 663,166.00 | -84.36 | -28.03 | -91.95 | -30.66 | -- | -- | -816.13 | -338.04 | -- | -56.80 | 1.48 | -- | 13.85 | 2.77 | -7.22 | -- | -- | -- |
| Labiana Health SA | 70.37m | 904.36k | 32.93m | 394.00 | 36.45 | 6.98 | 6.96 | 0.468 | 0.1251 | 0.1251 | 10.21 | 0.653 | 1.34 | 2.33 | 6.06 | 190,702.30 | 1.62 | -4.65 | 2.69 | -8.04 | 61.09 | 59.85 | 1.21 | -4.85 | 0.8573 | 1.23 | 0.6842 | -- | 13.33 | 6.49 | 105.73 | -17.33 | -11.04 | -- |
| Kohjin Bio Co Ltd | 28.33m | 3.92m | 33.26m | 167.00 | 8.49 | 1.05 | 5.56 | 1.17 | 140.79 | 140.79 | 1,017.95 | 1,137.25 | 0.5995 | 3.69 | 5.53 | 31,156,770.00 | 8.29 | -- | 11.44 | -- | 44.58 | -- | 13.83 | -- | 1.61 | -- | 0.2512 | -- | 9.14 | -- | 106.44 | -- | -- | -- |
| Rhone Ma Holdings Bhd | 45.41m | 2.90m | 33.41m | 205.00 | 15.48 | 0.8732 | 8.77 | 0.7357 | 0.0449 | 0.0449 | 0.7037 | 0.7959 | 0.8988 | 2.29 | 5.19 | -- | 5.87 | 6.05 | 7.20 | 7.35 | 30.65 | 27.97 | 6.53 | 6.64 | 2.05 | 17.24 | 0.1002 | 36.65 | 4.17 | 12.17 | 1.87 | 7.34 | -37.84 | 20.11 |
| Telomir Pharmaceuticals Inc | 0.00 | -9.46m | 33.82m | -- | -- | 5.67 | -- | -- | -0.3739 | -0.3739 | 0.00 | 0.2063 | 0.00 | -- | -- | -- | -266.47 | -- | -303.19 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.48 | -- | -- | -- |
| Elutia Inc | 17.73m | -19.32m | 34.11m | 51.00 | -- | -- | -- | 1.92 | -0.6006 | -0.6827 | 0.5347 | -1.03 | 0.5419 | 4.04 | 6.50 | 413,411.80 | -59.08 | -57.79 | -- | -128.41 | 45.97 | 42.77 | -109.03 | -92.86 | 0.396 | -- | -- | -- | -1.50 | -10.69 | -31.23 | -- | 2.54 | -- |
| Malin Corporation plc | 0.00 | 0.00 | 34.18m | 2.00 | -- | 0.7757 | 341.77 | -- | 0.00 | 0.00 | 0.00 | 10.18 | 0.00 | -- | -- | 0.00 | 0.00 | 8.14 | 0.00 | 8.56 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -- | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Erste Asset Management GmbHas of 29 Aug 2025 | 133.35k | 7.25% |
| Matejka & Partner Asset Management GmbHas of 29 Aug 2025 | 120.11k | 6.53% |
| amandea Verm�gensverwaltung AGas of 30 Sep 2025 | 20.00k | 1.09% |
| DFP Deutsche Finanz Portfolioverwaltung GmbHas of 30 Jun 2025 | 1.65k | 0.09% |
| LLB Invest Kapitalanlagegesellschaft mbHas of 29 Aug 2025 | 1.20k | 0.07% |
